Skip to main content
OpenTrials
Completed

NCT Number: NCT00983983

High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of long-term use of high fat/high calorie and high calorie diets in people with amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Barrow Neurological Institute/St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

Loading trial locations.

About this study

Weight loss is a common and severe symptom of amyotrophic lateral sclerosis (ALS), caused both from inadequate calorie intake and an increased metabolic rate. People with ALS are generally instructed to increase their calorie intake; however, the ideal amount and type of calories has not been studied. Several studies in an animal model of motor neuron disease have shown that a high fat/high calorie diet can increase survival by as much as 38%. Mice on a high fat diet also live longer than mice fed diets consisting of high protein or high sugar. We are therefore conducting a phase II safety, tolerability, and preliminary efficacy trial in ALS of high fat versus high calorie versus normal diet. The normal diet will be calculated based on the number of calories needed to replace each participant's measured daily calorie requirement.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of ALS
  • Male or female subjects aged 18 years or older
  • Must already be tolerating tube feedings through either a gastrostomy tube (G-tube or PEG) or jejunostomy tube (J-tube)
  • Must require non-invasive ventilation (BIPAP) for less than 10 hours/day
  • Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating.

Exclusion criteria

  • History of hepatitis including non-alcoholic steatohepatitis (NASH), cholecystectomy, prior biliary disease such as gallstones
  • History of diabetes
  • History of prior myocardial infarction or stroke
  • Laboratory values: Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 times the upper limit of normal or total bilirubin greater than 1.5 times the upper limit of normal
  • Allergy to soy, fish, or milk products

Treatment and study plan

Oxepa

Dietary Supplement

Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.

Jevity 1.5

Dietary Supplement

Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.

Jevity 1.0

Dietary Supplement

Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.

Primary outcomes

  1. Safety Outcomes: Frequency of Adverse Events

    Time frame: 5 months

  2. Serious Adverse Events

    Time frame: 5 months

    SAE were defined using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.

  3. Tolerability

    Time frame: 5 months

    Number of participants who completed the study on their assigned study intervention.

Secondary outcomes

  1. Rate of Change in ALSFRS-R in Units/Month

    Time frame: Over 5 months

    Rate of change in the ALS Functional Rating Scale-Revised, calculated in units/month. Negative numbers refer to worsening over time.

  2. Biomarkers of Body Composition and Lipid Metabolism

    Time frame: 5 months follow-up

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Muscular Dystrophy Association

Registry information

Official study title

Phase II Safety and Tolerability Study of High Fat/High Calorie Versus High Calorie Versus Optimal Nutrition in Subjects With Amyotrophic Lateral Sclerosis

Important dates

Study start
2009
Primary completion
2013
Study completion
2013
First posted
Sep 24, 2009
Registry last updated
Feb 27, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.